Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 14/20 | 0.73 |
| ▸ | MAPK9 | P45984 | 13/20 | 0.73 |
| ▸ | MAPK10 | P53779 | 11/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.54 |
| ▸ | CDK2 | P24941 | 2/20 | 0.54 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 5/20 | 0.50 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5096269 | 1.00 | MAPK8 (0.73) | MAPK8MAPK9MAPK10CYP2C9CCNE1 | |
| SCHEMBL3814615 | 0.92 | MAPK8 (0.73) | MAPK8MAPK9MAPK10CYP2C9CCNE1 | |
| SCHEMBL5093840 | 0.92 | MAPK8 (0.73) | MAPK8MAPK9MAPK10CYP2C9CCNE1 | |
| SCHEMBL5094141 | 0.84 | MAPK8 (1.00) | MAPK8MAPK9MAPK10CYP2C9CCNE1 | |
| SCHEMBL5102191 | 0.84 | MAPK8 (1.00) | MAPK8MAPK9MAPK10CYP2C9CCNE1 | |
| SCHEMBL5094025 | 0.82 | MAPK8 (0.72) | MAPK8MAPK9MAPK10CYP2C9CCNE1 | |
| SCHEMBL5095730 | 0.82 | MAPK8 (0.72) | MAPK8MAPK9MAPK10CYP2C9CCNE1 | |
| SCHEMBL5090208 | 0.81 | MAPK8 (0.73) | MAPK8MAPK9MAPK10CYP2C9CCNE1 | |
| SCHEMBL3805465 | 0.81 | MAPK8 (0.73) | MAPK8MAPK9MAPK10CYP2C9CCNE1 | |
| SCHEMBL5096365 | 0.81 | MAPK10 (0.69) | MAPK8MAPK9MAPK10CYP2C9CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399462-B2 | 4-[4-(4-benzyloxy-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexanol; autoimmune, inflammatory, metabolic, neurological diseases as well as cancer and pain | ROCHE PALO ALTO LLC (US) | 2013-03-19 | — | — | US | claimed |
| EP-2102194-A1 | SUBSTITUTED PYRIMIDINES AND THEIR USE AS JNK MODULATORS | F. Hoffmann-Roche AG (CH) | 2009-09-23 | — | — | EP | claimed |
| WO-2008068171-A9 | SUBSTITUTED PYRIMIDINES AND THEIR USE AS JNK MODULATORS | HOFFMANN LA ROCHE (CH) | 2009-07-16 | — | — | WO | claimed |
| US-20080146565-A1 | JNK modulators | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | claimed |
| WO-2008068171-A1 | SUBSTITUTED PYRIMIDINES AND THEIR USE AS JNK MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | claimed |
| US-8399462-B2 | 4-[4-(4-benzyloxy-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexanol; autoimmune, inflammatory, metabolic, neurological diseases as well as cancer and pain | ROCHE PALO ALTO LLC (US) | 2013-03-19 | — | — | US | disclosed |
| US-20080146565-A1 | JNK modulators | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146565-A1 | JNK modulators | MAPKAPK2, MAPKAPK3, MAP3K10 | MAPK8 40/4885MAPK9 43/4885MAPK10 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.